[go: up one dir, main page]

DK3242685T3 - Cxcr4-bindende molekyler - Google Patents

Cxcr4-bindende molekyler Download PDF

Info

Publication number
DK3242685T3
DK3242685T3 DK16734863.0T DK16734863T DK3242685T3 DK 3242685 T3 DK3242685 T3 DK 3242685T3 DK 16734863 T DK16734863 T DK 16734863T DK 3242685 T3 DK3242685 T3 DK 3242685T3
Authority
DK
Denmark
Prior art keywords
cxcr4
binding molecules
molecules
binding
Prior art date
Application number
DK16734863.0T
Other languages
English (en)
Inventor
Michael Foley
Andrew Pow
Katherine Griffiths
Samantha Cobb
Katerina Viduka
Original Assignee
Adalta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015900054A external-priority patent/AU2015900054A0/en
Application filed by Adalta Ltd filed Critical Adalta Ltd
Application granted granted Critical
Publication of DK3242685T3 publication Critical patent/DK3242685T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
DK16734863.0T 2015-01-09 2016-01-08 Cxcr4-bindende molekyler DK3242685T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015900054A AU2015900054A0 (en) 2015-01-09 CXCR4 binding molecules
PCT/AU2016/050005 WO2016109872A1 (en) 2015-01-09 2016-01-08 Cxcr4 binding molecules

Publications (1)

Publication Number Publication Date
DK3242685T3 true DK3242685T3 (da) 2022-07-25

Family

ID=56355354

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16734863.0T DK3242685T3 (da) 2015-01-09 2016-01-08 Cxcr4-bindende molekyler

Country Status (12)

Country Link
US (2) US10538596B2 (da)
EP (2) EP4112077A1 (da)
JP (3) JP6863897B2 (da)
CN (2) CN107427574B (da)
AU (3) AU2016206191B2 (da)
CA (1) CA2973317A1 (da)
DK (1) DK3242685T3 (da)
ES (1) ES2924394T3 (da)
HR (1) HRP20220860T1 (da)
LT (1) LT3242685T (da)
SG (2) SG11201705583XA (da)
WO (1) WO2016109872A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107427574B (zh) * 2015-01-09 2022-02-08 阿达尔塔有限公司 Cxcr4结合分子
KR102531889B1 (ko) 2016-06-20 2023-05-17 키맵 리미티드 항-pd-l1 및 il-2 사이토카인
EP3535293A1 (en) 2016-11-07 2019-09-11 Crossbeta Biosciences B.V. Novel amyloid beta oligomer specific binding molecule
WO2018130702A1 (en) * 2017-01-16 2018-07-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Improved multi tyrosine kinase inhibitor therapy
EP3727371A4 (en) * 2017-12-19 2021-10-27 GPCR Therapeutics, Inc. GPCR HETEROMER INHIBITORS AND THEIR USES
JP2022527351A (ja) * 2019-04-02 2022-06-01 イーライ リリー アンド カンパニー 結合ペプチドを選択し検出するための方法
US20220273751A1 (en) * 2019-05-17 2022-09-01 Gpcr Therapeutics, Inc. Gpcr heteromer inhibitors and uses thereof
JP7365674B2 (ja) * 2019-08-29 2023-10-20 国立大学法人 長崎大学 アスペルギローマモデル非ヒト動物
CN110804100A (zh) * 2019-11-01 2020-02-18 中国人民解放军陆军特色医学中心 融合多肽及其在增强干细胞归巢能力和抗凋亡能力中的应用和药物组合物
WO2023092177A1 (en) * 2021-11-23 2023-06-01 Adalta Limited Rank-l binding molecules
CN114533884A (zh) * 2022-04-20 2022-05-27 澳门大学 一种联合治疗癌症的药物及s100a9-cxcl12信号抑制剂的应用
WO2025010469A1 (en) * 2023-07-07 2025-01-16 Adalta Limited Linking receptor occupancy to efficacy of cxcr4 antagonists

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439A (en) 1846-04-04 Improvement in cleansing fish-oils
US4475A (en) 1846-04-25 Henry johnson
US196A (en) 1837-05-15 Machine for mowing and heaping grain
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5206154A (en) 1985-01-28 1993-04-27 Xoma Corporation Method of producing cecropins by microbiological techniques
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5215896A (en) 1987-03-20 1993-06-01 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
SE8804074D0 (sv) 1988-11-10 1988-11-10 Pharmacia Ab Sensorenhet och dess anvaendning i biosensorsystem
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DE69332740T2 (de) 1992-08-21 2004-02-05 The University Of British Columbia, Vancouver Kationische peptide und verfahren zu deren herstellung
US5648244A (en) 1993-09-27 1997-07-15 President And Fellows Of Harvard College Production, purification, cleavage and use of fusion peptides
US5485277A (en) 1994-07-26 1996-01-16 Physical Optics Corporation Surface plasmon resonance sensor and methods for the utilization thereof
US6037145A (en) 1994-09-07 2000-03-14 Suntory Limited Process for production of protein
US5567301A (en) 1995-03-01 1996-10-22 Illinois Institute Of Technology Antibody covalently bound film immunobiosensor
US5972639A (en) 1997-07-24 1999-10-26 Irori Fluorescence-based assays for measuring cell proliferation
DE19818790A1 (de) 1998-04-27 1999-10-28 Affina Immuntechnik Gmbh Immunadsorptionsmatrix, Verfahren zu ihrer Herstellung und ihre Verwendung
ES2292682T3 (es) 1998-05-06 2008-03-16 Genentech, Inc. Purificacion de anticuerpos mediante cromatografia de intercambio ionico.
WO2000006763A1 (en) 1998-07-31 2000-02-10 Pierce Chemical Company Fusion products containing insoluble proteinaceous tag
US6190908B1 (en) 1998-08-12 2001-02-20 The Scripps Research Institute Modulation of polypeptide display on modified filamentous phage
US6306610B1 (en) 1998-09-18 2001-10-23 Massachusetts Institute Of Technology Biological applications of quantum dots
US6242219B1 (en) 1999-03-18 2001-06-05 Xoma (Us) Llc Methods for recombinant peptide production
AU6267000A (en) 1999-06-30 2001-01-22 Evotec Oai Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
CA2406873A1 (en) 2000-04-25 2001-11-01 Chemicon International, Inc. Cell proliferation assay
AU2002220577A1 (en) 2000-09-28 2002-04-08 Affina Immuntechnik Gmbh Circulatory device for separating substances in bodily fluids, especially blood,and the use of said device
JP4636876B2 (ja) 2002-05-24 2011-02-23 メドトロニック，インコーポレイテッド ポリペプチドの高収率生産のための方法およびｄｎａ構築物
US8574590B2 (en) 2003-07-30 2013-11-05 Integral Molecular, Inc. Lipoparticles comprising proteins, methods of making, and using the same
WO2005108415A2 (en) * 2004-04-30 2005-11-17 Biogen Idec Ma Inc. Membrane associated molecules
EP2740743A3 (en) 2004-06-01 2015-08-19 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
US7977071B2 (en) * 2004-06-02 2011-07-12 Adalta Pty Ltd. Binding moieties based on shark ignar domains
US7671069B2 (en) 2006-03-30 2010-03-02 Chemocentryx, Inc. Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7
WO2007115231A2 (en) 2006-03-30 2007-10-11 Chemocentryx, Inc. Cxcr4 modulators
SG178712A1 (en) * 2006-10-02 2012-03-29 Medarex Inc Human antibodies that bind cxcr4 and uses thereof
US8088895B2 (en) 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
AU2007317203B2 (en) 2006-11-10 2010-12-16 Dimerix Bioscience Pty Ltd Detection system and uses therefor
US20080261978A1 (en) 2007-03-08 2008-10-23 Clark Michael P Chemokine receptor modulators
CN102088993A (zh) 2008-03-20 2011-06-08 卡罗勒斯治疗公司 炎症的治疗方法
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
KR101701367B1 (ko) 2008-11-04 2017-02-02 케모센트릭스, 인크. Ｃｘｃｒ７의 모듈레이터
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
KR102024957B1 (ko) * 2011-11-09 2019-09-24 브리스톨-마이어스 스큅 컴퍼니 항-cxcr4 항체를 이용한 혈액 악성종양의 치료
EP2964332A4 (en) * 2013-03-08 2016-09-14 Curonz Holdings Company Ltd NEURAL REGENERATION PEPTIDES AND USES THEREOF
CN107427574B (zh) * 2015-01-09 2022-02-08 阿达尔塔有限公司 Cxcr4结合分子

Also Published As

Publication number Publication date
ES2924394T3 (es) 2022-10-06
EP3242685A4 (en) 2018-07-11
AU2019203511A1 (en) 2019-06-06
WO2016109872A1 (en) 2016-07-14
EP4112077A1 (en) 2023-01-04
SG11201705583XA (en) 2017-08-30
SG10202111844VA (en) 2021-12-30
AU2016206191A1 (en) 2016-12-15
CN107427574A (zh) 2017-12-01
EP3242685A1 (en) 2017-11-15
AU2016206191A9 (en) 2017-01-19
JP2023015277A (ja) 2023-01-31
JP6863897B2 (ja) 2021-04-21
US20200231708A1 (en) 2020-07-23
EP3242685B1 (en) 2022-05-04
JP2020182479A (ja) 2020-11-12
AU2017254863A1 (en) 2017-11-16
US11142588B2 (en) 2021-10-12
JP2018504112A (ja) 2018-02-15
AU2019203511B2 (en) 2021-08-12
AU2016206191B2 (en) 2017-08-03
HRP20220860T1 (hr) 2022-10-14
CA2973317A1 (en) 2016-07-14
CN107427574B (zh) 2022-02-08
LT3242685T (lt) 2022-08-25
JP7212009B2 (ja) 2023-01-24
US10538596B2 (en) 2020-01-21
US20180072816A1 (en) 2018-03-15
CN114478773A (zh) 2022-05-13

Similar Documents

Publication Publication Date Title
DK3331869T3 (da) Muscarinagonister
DK3277719T3 (da) Polypeptider
DK3331528T3 (da) Muskarinagonister
DK3360890T3 (da) Genterapi
DK3331529T3 (da) Muskarinagonister
DK3310450T3 (da) Olie-vand-separator
DK3242685T3 (da) Cxcr4-bindende molekyler
EP3381654A4 (en) Liquid blow molding method
DK3270930T3 (da) Præeklampsi
DK3394281T3 (da) Gærcelle
DK3292136T3 (da) Penicillin-g-acylaser
EP3384016A4 (en) MANIPULATED PHAGEMIDES
DE112015006486A5 (de) Inkubationsrinne
EP3377179A4 (en) DEUTERED EPI-743
DK3274482T3 (da) Stenborsknop
DK3318308T3 (da) Badmintonketsjer
DE112015005898A5 (de) Gurtschlossbringer
DE112016005599A5 (de) Strahlungsgrill
EP3548009A4 (en) POLYMERIC NANOPARTICLES
ES1140083Y (es) Descompatactador tetrafunción
DE102015206660A8 (de) Plattenaufteilanlage
DK3606953T3 (da) Fgfr3-bindende molekyler
EP3381903A4 (en) PENTAFLUORSULFANYLPYRIDINE
EP3355962A4 (en) MICRO CASSETTE
EP3347241A4 (en) Protective buffer strap